Pfizer raises FY2026 revenue outlook to USD 60.5-62.5 billion

• Pfizer raised the midpoint of its 2026 revenue guidance by USD 500 million to USD 60.5 billion-USD 62.5 billion.
• Updated outlook reflects stronger non-COVID performance, offset by lower COVID-19 revenue expectations of about USD 4 billion versus about USD 5 billion.
• Adjusted diluted EPS guidance reaffirmed at USD 2.8-USD 3 despite an expected USD 0.1 hit from a USD 650 million acquired IPR&D charge.
• Second-quarter revenue was USD 15 billion, up 1% operationally; adjusted diluted EPS was USD 0.77.
• Plan assumes most Comirnaty sales land late in the year; low COVID-19 incidence seen limiting Paxlovid utilization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.